Our data indicate that the remission duration did not seem to influence the rate of NGAL-R/CD38 expression in the interpatient group; for instance, patient P51, in remission for 17 months, exhibited lower NGAL-R/CD38 CLL cell levels (0%/5%) than patient P46, in remission for 3 months (30%/25%). This evidence concerns the gene LCN2 and B-cell chronic lymphocytic leukemia.